Orally ingestible robotic drug delivery device overcomes barriers of the gastrointestinal environment

Oral drug delivery is the most common and cost-effective way to deliver a treatment. But drugs must make it through the harsh, acidic environment of the stomach, resist degradation by enzymes, penetrate the barrier posed by the mucus of the small intestine and overcome many other obstacles before they can be absorbed. Because of these challenges, many drugs-; including common drugs like insulin-; must be delivered through other means.

Investigators from Brigham and Women's Hospital--a founding member of the Mass General Brigham healthcare system--and MIT have developed RoboCap, an orally ingestible robotic drug delivery device that overcomes many of the challenges of the gastrointestinal environment to deliver its payload. The team tested the device in preclinical models using insulin and vancomycin, an antibiotic usually delivered intravenously. When ingested, RoboCap's gelatinous coating is dissolved in the stomach. The environment of the small intestine activates RoboCap, which vibrates and rotates to clear mucus, enhance mixing and deposit the drug payload in the small intestine where the drug is likely to be absorbed. In a swine model, RoboCap increased drug permeability for both insulin and vancomycin by more than 10-fold.

Peptides and proteins are important drugs, but the degradative environment of the gastrointestinal tract and poor absorption has limited the ability to deliver these drugs orally. RoboCap's mucus-clearing and churning movements are designed to overcome these barriers and help deliver drugs to where they are needed."

C. Giovanni Traverso, MB, BChir, PhD, Co-Corresponding Author, Division of Gastroenterology, Hepatology and Endoscopy at the Brigham and Department of Mechanical Engineering at MIT